Drug Type Natural Killer Cell Therapies |
Synonyms- |
Target |
Action inhibitors, agonists |
Mechanism HLA-G inhibitors(major histocompatibility complex, class I, G inhibitors), LILRB1 agonists(Leukocyte immunoglobulin-like receptor B1 agonists), LILRB2 agonists(Leukocyte immunoglobulin-like receptor subfamily B member 2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | United States | 08 Dec 2024 |